Sandu Pharmaceuticals
Sandu Pharmaceuticals Share Price Chart
Sandu Pharmaceuticals last traded at ₹36.40 (2026-10-13). Over the past month the stock moved -3.9%, three months the stock moved -17.5%, year the stock moved -22.9%. Its closing range over 52 weeks is ₹32.42 – ₹44.76, with the latest close 18.7% below the high.
Closing prices up to 2026-10-13.
About Sandu Pharmaceuticals
Incorporated in 1985, Sandu Pharmaceuticals Ltd is a manufacturer of Ayurvedic Medicines.[1]
Business Overview:[1] SPL is engaged in the business of manufacturing and trading of Ayurveda based medicines under the brand name SANDU
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Sandu Pharmaceuticals reported sales of ₹16.39 crore (-1.9%) and net profit of ₹0.23 crore (+4.5%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 16.39 | 0.53 | 3.23 | 0.23 | 0.24 |
| Mar 2026 | 16.85 | 0.57 | 3.38 | 0.04 | 0.04 |
| Dec 2025 | 18.76 | 1.04 | 5.54 | 0.98 | 1.01 |
| Sep 2025 | 17.62 | 0.86 | 4.88 | 0.52 | 0.54 |
| Jun 2025 | 16.70 | 0.53 | 3.17 | 0.22 | 0.23 |
| Mar 2025 | 14.07 | 0.45 | 3.20 | 0.33 | 0.34 |
| Dec 2024 | 18.37 | 1.00 | 5.44 | 0.56 | 0.58 |
| Sep 2024 | 17.70 | 0.92 | 5.20 | 0.50 | 0.52 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +6.6% | +5.4% | -9.8% | -2.1% | -0.5% | +2.1% | +19.8% | -1.9% |
| Operating profit growth | +12.2% | +96.1% | -25.0% | +29.3% | -6.5% | +4.0% | +26.7% | +0.0% |
| Net profit growth | -9.1% | +166.7% | -44.1% | +29.4% | +4.0% | +75.0% | -87.9% | +4.5% |
| EPS growth | -8.8% | +163.6% | -44.3% | +27.8% | +3.8% | +74.1% | -88.2% | +4.3% |
| OPM % | 5.2% | 5.4% | 3.2% | 3.2% | 4.9% | 5.5% | 3.4% | 3.2% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Sandu Pharmaceuticals reported sales of ₹69.93 crore (+4.1%) and net profit of ₹1.77 crore (+14.2%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 69.93 | 3.00 | 4.29 | 1.77 | 1.83 |
| Mar 2025 | 67.19 | 2.76 | 4.11 | 1.55 | 1.60 |
| Mar 2024 | 67.28 | 2.30 | 3.42 | 1.46 | 1.51 |
| Mar 2023 | 65.35 | 2.49 | 3.81 | 1.52 | 1.57 |
| Mar 2022 | 65.50 | 2.88 | 4.40 | 1.59 | 1.80 |
| Mar 2021 | 58.76 | 2.16 | 3.68 | 1.09 | 1.38 |
| Mar 2020 | 48.37 | 1.45 | 3.00 | 0.72 | 1.02 |
| Mar 2019 | 49.42 | 2.09 | 4.23 | 0.67 | 0.95 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +0.8% | -2.1% | +21.5% | +11.5% | -0.2% | +3.0% | -0.1% | +4.1% |
| Operating profit growth | -15.4% | -30.6% | +49.0% | +33.3% | -13.5% | -7.6% | +20.0% | +8.7% |
| Net profit growth | +19.6% | +7.5% | +51.4% | +45.9% | -4.4% | -3.9% | +6.2% | +14.2% |
| EPS growth | +20.3% | +7.4% | +35.3% | +30.4% | -12.8% | -3.8% | +6.0% | +14.4% |
| OPM % | 4.2% | 3.0% | 3.7% | 4.4% | 3.8% | 3.4% | 4.1% | 4.3% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Sandu Pharmaceuticals.
Get Free AI Stock Analysis FREE →Latest News
-
Sandu Pharmaceuticals standalone net profit rises 4.55% in the June 2026 quarter - Business Standard
-
Sandu Pharmaceuticals standalone net profit declines 87.88% in the March 2026 quarter - Business Standard
-
Sandu Pharmaceuticals standalone net profit declines 87.88% in the March 2026 quarter - Business Standard
-
Sandu Pharmaceuticals Reports FY26 Net Profit of Rs. 176.61 Lakhs; Recommends Rs. 1 Per Share Dividend - scanx.trade
Frequently Asked Questions
What is Sandu Pharmaceuticals's current stock price?
Sandu Pharmaceuticals shares were last quoted at ₹36.40 (-0.2% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Sandu Pharmaceuticals?
Sandu Pharmaceuticals has a price-to-earnings (P/E) ratio of 23.44 and a price-to-book (P/B) ratio of 0.90. The industry P/E is 53.45.
What is the 52-week high and low of Sandu Pharmaceuticals?
The 52-week high of Sandu Pharmaceuticals is ₹50.00 and the 52-week low is ₹30.00.
What is the market cap of Sandu Pharmaceuticals?
The market capitalisation of Sandu Pharmaceuticals is about ₹36.46 crore.
How did Sandu Pharmaceuticals perform in its latest quarterly results?
In the latest quarter (Jun 2026), Sandu Pharmaceuticals reported sales of ₹16.39 crore (-1.9%) and net profit of ₹0.23 crore (+4.5%), compared with the same quarter last year.
Is Sandu Pharmaceuticals a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Sandu Pharmaceuticals has a 3-year ROE of 4.00%, 3-year profit growth of 5.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Sandu Pharmaceuticals?
Promoters hold about 37.79% of Sandu Pharmaceuticals.
Which sector does Sandu Pharmaceuticals belong to?
Sandu Pharmaceuticals belongs to the Pharmaceuticals & Drugs sector.